How to Help Your Patients Save Money on Lagevrio: A Provider's Guide to Savings Programs

When you prescribe Lagevrio (molnupiravir) for a COVID-positive patient, cost can be as significant a barrier to treatment as availability. At approximately $1,100–$1,170 retail for a 5-day course, Lagevrio is a major out-of-pocket expense for uninsured or underinsured patients. This guide gives you the tools and workflow to address cost barriers at the point of prescribing — before they become barriers to care.

Why Addressing Cost Barriers at the Point of Care Matters

Studies consistently show that patients who cannot afford their medications simply don't take them — and in the case of COVID antivirals, delayed or missed treatment directly increases the risk of hospitalization and death. With Lagevrio's 5-day treatment window, there's no time for a patient to discover the cost problem after prescribing, figure out the assistance programs, enroll, and still get treated in time. The cost solution needs to happen at the moment of prescribing.

Program 1: MerckHelps Patient Assistance Program

The MerckHelps patient assistance program provides Lagevrio at no cost to eligible uninsured patients who cannot otherwise afford it. This is the most critical program for vulnerable patients who would otherwise go untreated.

Contact: 1-800-727-5400 | merckhelps.com/lagevrio

Who qualifies: Primarily uninsured patients unable to afford the medication. Patients with insurance who face financial hardship may qualify under special circumstances if their income meets program criteria.

Expedited requests: Providers or their designees can initiate expedited requests by calling 1-800-727-5400. If approved, Lagevrio can be shipped overnight to the patient's home address — bypassing the pharmacy availability problem entirely.

Provider role: You or your designee may be able to enroll the patient directly from your office, saving them the effort of navigating the program themselves.

Program 2: Merck Savings Coupon for Commercially Insured Patients

Patients with private commercial insurance may be eligible for a Merck savings coupon that reduces their out-of-pocket cost. This is especially relevant for patients with high-deductible health plans or plans that place Lagevrio on a higher formulary tier.

Direct patients and caregivers to lagevrio.com/patients/coupon to check eligibility and obtain the coupon before heading to the pharmacy. The coupon is not applicable for patients with federal insurance (Medicare, Medicaid, TRICARE, VA).

Medicare Part D: Understanding Coverage and Copays

For Medicare patients, Lagevrio is typically covered under Part D with Tier 1 placement on most formularies — meaning the lowest copay tier. In practice, most Medicare Part D beneficiaries pay $10–$50 per course. Key points for providers:

Lagevrio must be billed through Part D (outpatient prescription drug coverage) — not Part A or Part B

The 2025/2026 Medicare Part D $2,000 annual out-of-pocket cap provides a safety net if patients reach the catastrophic coverage phase

For uninsured Medicare beneficiaries, the MerckHelps program is available since there is no longer a government-specific subsidy for Lagevrio under Medicare

Understanding the Coverage Landscape: Who Pays What?

Here is a reference guide for the coverage scenarios your patients may present with:

Uninsured: Retail price ~$1,100–$1,170. MerckHelps may provide at $0 if eligible. GoodRx may reduce to ~$993.

Private insurance: Copay typically $10–$50 with most plans. Merck savings coupon can reduce further. Prior auth generally not required.

Medicare Part D: Tier 1 on most formularies. Copay ~$10–$50. No government subsidy program specifically for Lagevrio.

Medicaid: Coverage varies by state. Most Medicaid programs cover Lagevrio with minimal or zero copay for eligible enrollees.

Addressing Prior Authorization Concerns

Most insurance plans do not require prior authorization for Lagevrio given its emergency-use context and the time-sensitive nature of treatment. However, if you encounter a plan requiring prior authorization, frame the urgency explicitly in your submission: the patient has a 5-day treatment window from symptom onset, and delay will render treatment ineffective. This is generally sufficient to trigger expedited review.

Recommended Practice Workflow for Cost Access

Ask about insurance status before prescribing — identify which cost pathway is appropriate

For uninsured patients: Initiate MerckHelps enrollment from your office (1-800-727-5400). Expedited requests can result in overnight delivery.

For privately insured patients: Provide the Merck savings coupon information (lagevrio.com/patients/coupon)

Verify pharmacy availability simultaneously — use medfinder for Providers to confirm a pharmacy has Lagevrio in stock before sending the prescription

Route prescription to confirmed pharmacy — don't leave the patient to find a pharmacy on their own

The Dual Challenge: Cost AND Availability

Your patients face two simultaneous challenges with Lagevrio: finding it in stock and affording it. Both must be solved within the 5-day window. medfinder for Providers addresses the availability side, while the programs above address the cost side. A proactive workflow that handles both at the point of prescribing is the best way to ensure your patients actually complete their treatment.

For a complete clinical briefing on Lagevrio availability in 2026, see our Lagevrio shortage guide for providers.